Josh Bartch of Mydecine Innovations Group

Josh Bartch is the CEO of Mydecine Innovations Group, a psychedelics company that is researching naturally sourced psychedelic therapeutics targeting PTSD and smoking cessation.  In this episode of The Integration Conversation, Josh joins us for a full hour and tells us about Mydecine's clinical trials, its research on functional mushrooms, and makes his pitch for why Mydecine is undervalued relative to its peers.  

Questions we answer:

• Is Mydecine Undervalued?
• What lessons from the cannabis boom can we apply to the shroom boom?
• Is natural psilocybin better than synthetic psilocybin?
• What is the entourage effect?